Evaluation of immunogenicity and protective efficacy of a novel Senecavirus A strain-based inactivated vaccine in mice

Li, Ning; Qiao, Qilong; Guo, Huifang; Wang, Bai-yu; Huang, Qing; Wang, Zeng; Li, Yongtao; Zhao, Jingpeng

doi:10.1016/j.rvsc.2021.12.010

Cited by 9 publications

(19 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gene copies in the heart, liver, spleen, and lung tissues were more regular and had a higher level, consistent with the tropism of SVA for various organs in naturally infected newborn piglets ( 39 ). Histopathological examination showed that SVA can cause cardiac hemorrhage, endocarditis, balloon-like degeneration, and cytoplasmic vacuolation of hepatocytes, similar to SVA CH-HNCY-2019-infected mice ( 38 ). However, no significant pathological changes were observed in other tissues of SVA-infected mice, which may be due to differences in virus strain, challenge dose, and sample collection time.…”

Section: Discussionmentioning

confidence: 88%

“…A study has demonstrated that mice can serve as a suitable animal model for an initial evaluation of the immunogenicity and protective efficacy of vaccines against SVA ( 38 ). Oral challenge with 2 × 10 −7 TCID 50 of SVA CH-HNCY-2019 can cause significant pathological changes in the heart, lung, liver, spleen, kidney, brain and duodenum tissue of mice.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The Construction and Immunogenicity Analyses of a Recombinant Pseudorabies Virus with Senecavirus A VP2 Protein Coexpression

Tao

Zhu

et al. 2023

Microbiol Spectr

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 88%

Section: Discussionmentioning

confidence: 99%

The Construction and Immunogenicity Analyses of a Recombinant Pseudorabies Virus with Senecavirus A VP2 Protein Coexpression

Tao

Zhu

et al. 2023

Microbiol Spectr

View full text Add to dashboard Cite

show abstract

“…A mouse model for SVA infection [ 29 ], established by oral challenge with SVA, was used for in vivo verification of the in vitro PK-15 cell results ( Fig 7A ). At 7 days post infection (d.p.i.…”

Section: Resultsmentioning

confidence: 99%

“…All mice were maintained in pathogen free barrier facilities and randomly assigned to 7 groups (negative control, SVA-high glucose, SVA-low glucose, SVA-oxamate, SVA-lactate, SVA-oxamate + lactate, and SVA-challenged group), with 5 mice in each group. The mice were infected with SVA at 2×10 −7 TCID 50 based on the mouse infection model described by Li et al [ 29 ] and were treated with different reagents dissolved in PBS at 5 d.p.i. and 6 d.p.i.…”

Section: Methodsmentioning

confidence: 99%

Senecavirus A-induced glycolysis facilitates virus replication by promoting lactate production that attenuates the interaction between MAVS and RIG-I

Lin

et al. 2023

PLoS Pathog

View full text Add to dashboard Cite

Senecavirus A (SVA)-induced porcine idiopathic vesicular disease has caused huge economic losses worldwide. Glucose metabolism in the host cell is essential for SVA proliferation; however, the impact of the virus on glucose metabolism in host cells and the subsequent effects are still unknown. Here, glycolysis induced by SVA is shown to facilitate virus replication by promoting lactate production, which then attenuates the interaction between the mitochondrial antiviral-signaling protein (MAVS) and retinoic acid-inducible gene I (RIG-I). SVA induces glycolysis in PK-15 cells, as indicated by significantly increased expression of hexokinase 2 (HK2), 6-phosphofructokinase (PFKM), pyruvate kinase M (PKM), phosphoglycerate kinase 1 (PGK1), hypoxia-inducible factor-1 alpha (HIF-1α), and superoxide dismutase-2 (SOD2) in a dose-and replication-dependent manner, and enhanced lactate production, while reducing ATP generation. Overexpression of PKM, PGK1, HIF-1α, and PDK3 in PK-15 cells and high glucose concentrations promote SVA replication, while glycolytic inhibitors decrease it. Inhibition of RLR signaling allowed better replication of SVA by promoting lactate production to attenuate the interaction between MAVS and RIG-I, and regulatory effect of glycolysis on replication of SVA was mainly via RIG-I signaling. SVA infection in mice increased expression of PKM and PGK1 in tissues and serum yields of lactate. Mice treated with high glucose and administered sodium lactate showed elevated lactate levels and better SVA replication, as well as suppressed induction of RIG-I, interferon beta (IFNβ), IFNα, interferon-stimulated gene 15 (ISG15), and interleukin 6 (IL-6). The inhibitory effect on interferons was lower in mice administered sodium oxamate and low glucose compared to the high glucose, indicating that RLR signaling was inhibited by SVA infection through lactate in vitro and in vivo. These results provide a new perspective on the relationship between metabolism and innate immunity of the host in SVA infection, suggesting that glycolysis or lactate may be new targets against the virus.

show abstract

“…Formalin, binary ethylenimine (BEI), and β-Propiolactone (BPL) are often used for viral inactivation [ 16 , 18 , 26 , 27 ]. Among these inactivators, BEI is widely used in FMD vaccine development [ 28 ] and was selected for inactivating the CH-GX-01-2019 SVA strain.…”

Section: Discussionmentioning

confidence: 99%

Adjuvant screening of the Senecavirus A inactivated vaccine in mice and evaluation of its immunogenicity in pigs

Zhang,

Wang,

et al. 2024

BMC Vet Res

View full text Add to dashboard Cite

Background Senecavirus A (SVA) causes an emerging vesicular disease (VD) with clinical symptoms indistinguishable from other vesicular diseases, including vesicular stomatitis (VS), foot-and-mouth disease (FMD), and swine vesicular disease (SVD). Currently, SVA outbreaks have been reported in Canada, the U.S.A, Brazil, Thailand, Vietnam, Colombia, and China. Based on the experience of prevention and control of FMDV, vaccines are the best means to prevent SVA transmission. Results After preparing an SVA inactivated vaccine (CH-GX-01-2019), we evaluated the immunogenicity of the SVA inactivated vaccine mixed with Imject® Alum (SVA + AL) or Montanide ISA 201 (SVA + 201) adjuvant in mice, as well as the immunogenicity of the SVA inactivated vaccine combined with Montanide ISA 201 adjuvant in post-weaned pigs. The results of the mouse experiment showed that the immune effects in the SVA + 201 group were superior to that in the SVA + AL group. Results from pigs immunized with SVA inactivated vaccine combined with Montanide ISA 201 showed that the immune effects were largely consistent between the SVA-H group (200 µg) and SVA-L group (50 µg); the viral load in tissues and blood was significantly reduced and no clinical symptoms occurred in the vaccinated pigs. Conclusions Montanide ISA 201 is a better adjuvant choice than the Imject® Alum adjuvant in the SVA inactivated vaccine preparation, and the CH-GX-01-2019 SVA inactivated vaccine can provide effective protection for pigs.

show abstract

Evaluation of immunogenicity and protective efficacy of a novel Senecavirus A strain-based inactivated vaccine in mice

Cited by 9 publications

References 37 publications

The Construction and Immunogenicity Analyses of a Recombinant Pseudorabies Virus with Senecavirus A VP2 Protein Coexpression

The Construction and Immunogenicity Analyses of a Recombinant Pseudorabies Virus with Senecavirus A VP2 Protein Coexpression

Senecavirus A-induced glycolysis facilitates virus replication by promoting lactate production that attenuates the interaction between MAVS and RIG-I

Adjuvant screening of the Senecavirus A inactivated vaccine in mice and evaluation of its immunogenicity in pigs

Contact Info

Product

Resources

About